NASDAQ:HELP Cybin Q4 2024 Earnings Report $12.70 +0.11 (+0.87%) Closing price 04:00 PM EasternExtended Trading$12.78 +0.08 (+0.62%) As of 04:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Cybin EPS ResultsActual EPS-$0.04Consensus EPS -$0.02Beat/MissMissed by -$0.02One Year Ago EPSN/ACybin Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACybin Announcement DetailsQuarterQ4 2024Date6/26/2024TimeN/AConference Call DateWednesday, June 26, 2024Conference Call Time7:00AM ETConference Call ResourcesAnnual Report (40-F)Earnings HistoryCompany ProfilePowered by Earnings DocumentsAnnual Report(40-F) Cybin Earnings HeadlinesCybin Inc (HELP)3 hours ago | fr.investing.comCybin (HELP) Stock May Be Trading At A Premium Despite Fresh Depression Trial DataSeptember 24, 2026 | uk.finance.yahoo.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.September 29 at 1:00 AM | The Oxford Club (Ad)Cybin (HELP) Shares Moved, What Is Behind The Fresh Attention?September 24, 2026 | finance.yahoo.comHelus Pharma Announces Annual and Special Meeting Voting Results and Legal Name Change to Helus Pharma Inc.September 22, 2026 | quiverquant.comQHelus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name ChangeSeptember 22, 2026 | globenewswire.comSee More Cybin Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cybin? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cybin and other key companies, straight to your email. Email Address About CybinCybin (NASDAQ:HELP) is a clinical-stage biopharmaceutical company focused on developing psychedelic-based therapeutics for the treatment of mental health conditions. The company combines drug discovery, clinical development and proprietary formulation technologies to design potentially more efficient and scalable psychedelic treatments. Cybin’s development programs have included CYB003, an investigational deuterated psilocybin analog being studied for major depressive disorder, and CYB004, an investigational deuterated DMT molecule being evaluated for generalized anxiety disorder and other mental health indications. The company has also developed proprietary delivery technologies intended to support consistent dosing and administration. Founded in 2019, Cybin is headquartered in Canada and conducts research and clinical development activities in North America and other regions through its programs and partnerships. Its work remains subject to clinical testing and regulatory review, and its investigational products have not been approved for commercial use.View Cybin ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles CarMax Just Gave Investors a Better Reason to Believe in the TurnaroundBernstein Downgrades 3 Cybersecurity Stocks: How Concerned Should Investors Be?Brewing Trouble? Starbucks Spills the Beans on 250 Store ClosuresMarketBeat Week in Review – 09/21 - 09/25Analyst Rating Boosts May Signal More Upside for These 3 Stocks3 Stocks Under the Microscope After Large Insider Sales3 Healthcare Stocks Showing Why the Sector Still Has Momentum Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
